Literature DB >> 8866387

Predictors of persistent disease in women with complete hydatidiform mole.

A Ayhan1, Z S Tuncer, H Halilzade, T Küçükali.   

Abstract

OBJECTIVE: To determine the most significant factors for persistent disease in women with hydatidiform mole. STUDY
DESIGN: Eighty-two patients who were managed consecutively without prophylactic chemotherapy between 1973 and 1993 were analyzed retrospectively for clinical and pathologic features, including age of the patient, size of the uterus, human chorionic gonadotropin (hCG) level, presence of theca lutein cysts, evidence of preeclampsia or hyperthyroidism, history of hydatidiform moles, trophoblastic hyperplasia, nuclear atypia, necrosis and hemorrhage, trophoblastic maturation, presence of fibrinoid layer and ratio of cytotrophoblast to syncytial trophoblast.
RESULTS: Thirty-one patients developed persistent trophoblastic neoplasia (38%). Of the parameters evaluated, elevated hCG level, advanced age, history of hydatidiform mole, presence of hyperplasia, marked nuclear atypia and necrosis, and hemorrhage were significant risk factors for persistent neoplasia after univariate analysis. Among the factors analyzed, trophoblastic hyperplasia (relative ration [RR] = 3.56), age (RR = 2.87) and history of mole (RR = 2.57) were identified as the most powerful indicators of persistent disease after multivariate analysis.
CONCLUSION: Evaluation of the clinical and pathologic features, such as age, history of mole and presence of trophoblastic proliferation may aid in defining a subset of patients at high risk for persistent disease, who require closer follow-up and administration of prophylactic chemotherapy.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8866387

Source DB:  PubMed          Journal:  J Reprod Med        ISSN: 0024-7758            Impact factor:   0.142


  4 in total

1.  Combined analysis of clinical features, human chorionic gonadotropin (hCG) value, and hCG ratios for early prediction of postmolar gestational trophoblastic neoplasia.

Authors:  Chanya Rakprasit; Irene Ruengkhachorn; Suwanit Therasakvichya; Perapong Inthasorn; Vuthinun Achariyapota; Sompop Kuljarasnont; Khemanat Khemworapong; Nida Jareemit
Journal:  Arch Gynecol Obstet       Date:  2022-09-18       Impact factor: 2.493

2.  The evolution of methotrexate as a treatment for ectopic pregnancy and gestational trophoblastic neoplasia: a review.

Authors:  Monika M Skubisz; Stephen Tong
Journal:  ISRN Obstet Gynecol       Date:  2012-02-19

3.  Complementary Role of Ultrasound in Management of Gestational Trophoblastic Disease.

Authors:  Mahrooz Malek; Behnaz Moradi; Azam Sadat Mousavi; Nasrin Ahmadinejad; Mohamad Ali Kazemi; Masoumeh Gity
Journal:  Iran J Radiol       Date:  2015-02-07       Impact factor: 0.212

4.  Does Postevacuation β -Human Chorionic Gonadotropin Level Predict the Persistent Gestational Trophoblastic Neoplasia?

Authors:  Azam Sadat Mousavi; Samieh Karimi; Mitra Modarres Gilani; Setareh Akhavan; Elahe Rezayof
Journal:  ISRN Obstet Gynecol       Date:  2014-03-24
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.